|
ZA935112B
(en)
*
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
US5260300A
(en)
|
1992-11-19 |
1993-11-09 |
American Home Products Corporation |
Rapamycin carbonate esters as immuno-suppressant agents
|
|
WO1994025072A1
(en)
|
1993-04-23 |
1994-11-10 |
American Home Products Corporation |
Rapamycin conjugates and antibodies
|
|
EP0729471A1
(en)
|
1993-11-19 |
1996-09-04 |
Abbott Laboratories |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
|
BR9408323A
(pt)
|
1993-12-17 |
1997-08-19 |
Sandoz Ag |
Derivados de rapamicina
|
|
US5362735A
(en)
|
1994-02-23 |
1994-11-08 |
Smithkline Beecham Corporation |
Rapamycin derivatives
|
|
US5639600A
(en)
|
1994-08-05 |
1997-06-17 |
The Regents Of The University Of California |
Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
|
|
JP3934705B2
(ja)
*
|
1995-05-26 |
2007-06-20 |
ノバルティス ファーマ株式会社 |
サイクロデキストリン組成物
|
|
KR19990022651A
(ko)
|
1995-06-07 |
1999-03-25 |
데이비드 엘. 버스테인 |
생물학적 사건에 대한 라파마이신 기재 조절방법
|
|
DE69624921T2
(de)
|
1995-06-09 |
2003-09-11 |
Novartis Ag, Basel |
Rapamycinderivate
|
|
WO1998002441A2
(en)
*
|
1996-07-12 |
1998-01-22 |
Ariad Pharmaceuticals, Inc. |
Non immunosuppressive antifungal rapalogs
|
|
CA2257803C
(en)
|
1996-07-12 |
2008-12-02 |
Ariad Pharmaceuticals, Inc. |
Non immunosuppressive antifungal rapalogs
|
|
CN1235608A
(zh)
|
1996-09-09 |
1999-11-17 |
美国家用产品公司 |
烷基化的雷帕霉素衍生物
|
|
US5922730A
(en)
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
|
US6342507B1
(en)
|
1997-09-05 |
2002-01-29 |
Isotechnika, Inc. |
Deuterated rapamycin compounds, method and uses thereof
|
|
US7087648B1
(en)
|
1997-10-27 |
2006-08-08 |
The Regents Of The University Of California |
Methods for modulating macrophage proliferation using polyamine analogs
|
|
WO1999036553A2
(en)
*
|
1998-01-15 |
1999-07-22 |
Ariad Gene Therapeutics, Inc. |
Regulation of biological events using multimeric chimeric proteins
|
|
US7067526B1
(en)
|
1999-08-24 |
2006-06-27 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
|
IL147803A0
(en)
|
1999-08-24 |
2002-08-14 |
Ariad Gene Therapeutics Inc |
28-epirapalogs
|
|
TWI256395B
(en)
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
|
OA12118A
(en)
|
1999-12-10 |
2006-05-04 |
Pfizer Prod Inc |
PyrroloÄ2,3-dÜpyrimidine compounds.
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
KR100833371B1
(ko)
|
2001-04-27 |
2008-05-28 |
젠야쿠코교가부시키가이샤 |
헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US20040001878A1
(en)
*
|
2002-06-26 |
2004-01-01 |
Deroyal Industries, Inc. |
Infused wound care dressings
|
|
MXPA05001766A
(es)
|
2002-08-14 |
2005-08-19 |
Atugen Ag |
Uso de proteina quinasa n beta.
|
|
WO2004089925A1
(en)
|
2003-04-03 |
2004-10-21 |
Semafore Pharmaceuticals, Inc. |
Pi-3 kinase inhibitor prodrugs
|
|
ES2382377T3
(es)
|
2003-05-30 |
2012-06-07 |
Gemin X Pharmaceuticals Canada Inc. |
Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
|
|
WO2005007623A2
(en)
|
2003-07-03 |
2005-01-27 |
The Trustees Of The University Of Pennsylvania |
Inhibition of syk kinase expression
|
|
CA2531454C
(en)
*
|
2003-07-08 |
2011-10-25 |
Novartis Ag |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
|
US7220755B2
(en)
*
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
|
LT2612862T
(lt)
|
2004-05-13 |
2017-01-25 |
Icos Corporation |
Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
|
|
US20060189551A1
(en)
*
|
2004-10-04 |
2006-08-24 |
Duke University |
Combination therapies for fungal pathogens
|
|
US7449458B2
(en)
|
2005-01-19 |
2008-11-11 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
|
US20060257337A1
(en)
|
2005-04-28 |
2006-11-16 |
David Sherris |
Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
|
|
ES2493466T3
(es)
|
2005-05-12 |
2014-09-11 |
Abbvie Bahamas Ltd. |
Promotores de la apoptosis
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
HRP20140975T1
(hr)
|
2005-10-07 |
2014-11-21 |
Exelixis, Inc. |
Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
|
|
HRP20130902T1
(hr)
|
2005-10-07 |
2013-11-08 |
Exelixis Inc. |
PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
|
|
WO2007053452A1
(en)
|
2005-11-01 |
2007-05-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
CA2630271C
(en)
|
2005-11-17 |
2014-04-08 |
Osi Pharmaceuticals, Inc. |
Fused bicyclic mtor inhibitors
|
|
HUE028588T2
(hu)
|
2005-12-13 |
2016-12-28 |
Incyte Holdings Corp |
Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
US20070203168A1
(en)
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
|
|
AR060391A1
(es)
|
2006-04-11 |
2008-06-11 |
Smithkline Beecham Corp |
Compuestos de quinolin tiazolidinadiona, sustituidos con heterociclos, composiciones farmaceuticas que los contienen y usos para preparar medicamentos que inhiben la actividad de pi3 quinasas.
|
|
KR101533461B1
(ko)
|
2006-04-26 |
2015-07-02 |
에프. 호프만-라 로슈 아게 |
Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
|
|
US20080026591A1
(en)
|
2006-07-28 |
2008-01-31 |
Caracal, Inc. |
Sintered metal components for crystal growth reactors
|
|
CA2663401C
(en)
|
2006-09-15 |
2011-07-12 |
Pfizer Products Inc. |
Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
|
|
EP2529621B1
(en)
|
2006-09-22 |
2016-10-05 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase
|
|
PE20081679A1
(es)
|
2006-12-07 |
2008-12-18 |
Hoffmann La Roche |
Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
|
|
WO2008110491A2
(en)
|
2007-03-09 |
2008-09-18 |
University Of Basel |
Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
|
|
HUE029188T2
(en)
|
2007-03-12 |
2017-03-28 |
Ym Biosciences Australia Pty |
Phenylamino-pyrimidine compounds and their use
|
|
US8394794B2
(en)
|
2007-03-23 |
2013-03-12 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
MY165582A
(en)
|
2008-03-11 |
2018-04-05 |
Incyte Holdings Corp |
Azetidine and cyclobutane derivatives as jak inhibitors
|
|
US20090253733A1
(en)
|
2008-04-02 |
2009-10-08 |
Biointeractions, Ltd. |
Rapamycin carbonate esters
|
|
MY155653A
(en)
|
2008-05-23 |
2015-11-13 |
Wyeth Llc |
Triazine compounds as p13 kinase and mtor inhibitors
|
|
WO2009153597A2
(en)
|
2008-06-20 |
2009-12-23 |
Astrazeneca Ab |
Composition and process - 356
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
ES2345241B1
(es)
|
2009-03-16 |
2011-09-08 |
Lipopharma Therapeutics |
Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
|
|
CA2756067A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
DK2414362T3
(da)
|
2009-04-03 |
2014-09-22 |
Verastem Inc |
Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
|
|
WO2010118208A1
(en)
|
2009-04-09 |
2010-10-14 |
Exelixis, Inc. |
Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
|
|
US20130035336A1
(en)
|
2010-04-13 |
2013-02-07 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
|
|
US9062046B2
(en)
|
2010-07-16 |
2015-06-23 |
Piramal Enterprises Limited |
Substituted imidazoquinoline derivatives as kinase inhibitors
|
|
JO3003B1
(ar)
|
2011-01-14 |
2016-09-05 |
Lilly Co Eli |
مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
|
|
US8808256B2
(en)
|
2012-01-16 |
2014-08-19 |
Johnson & Johnson Vision Care, Inc. |
Eye drug delivery system
|
|
US9072678B2
(en)
|
2013-03-14 |
2015-07-07 |
Pathak Holdings Llc |
Methods for local drug delivery by microinjection
|
|
WO2015051043A1
(en)
|
2013-10-01 |
2015-04-09 |
Amgen Inc. |
Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
|
|
DK3102576T3
(da)
|
2014-02-03 |
2019-07-22 |
Vitae Pharmaceuticals Llc |
Dihydropyrrolopyridininhibitorer af ror-gamma
|
|
EP3193902A4
(en)
|
2014-09-11 |
2018-03-28 |
The Regents of The University of California |
mTORC1 INHIBITORS
|
|
US20160279108A1
(en)
|
2015-02-24 |
2016-09-29 |
University Of Kansas |
Targeted mtor inhibitors
|
|
US10683308B2
(en)
*
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
CA3061907A1
(en)
|
2017-05-02 |
2018-11-08 |
Revolution Medicines, Inc. |
Rapamycin analogs as mtor inhibitors
|
|
UY37900A
(es)
|
2017-09-26 |
2019-04-30 |
Novartis Ag |
Nuevos derivados de rapamicina
|
|
US10980784B2
(en)
*
|
2018-06-15 |
2021-04-20 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
WO2020076738A2
(en)
*
|
2018-10-12 |
2020-04-16 |
Bellicum Pharmaceuticals, Inc |
Protein-binding compounds
|
|
LT3898637T
(lt)
|
2018-12-18 |
2025-03-10 |
Novartis Ag |
Rapamicino dariniai
|
|
CA3127448C
(en)
*
|
2019-01-22 |
2024-06-04 |
Aeovian Pharmaceuticals, Inc. |
Mtorc modulators and uses thereof
|
|
KR20260115158A
(ko)
|
2019-03-26 |
2026-07-23 |
노파르티스 아게 |
이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도
|
|
EP4069223A4
(en)
*
|
2019-12-05 |
2023-12-20 |
Janssen Pharmaceutica NV |
RAPAMYCIN ANALOGS AND THEIR USES
|
|
CN115776907B
(zh)
|
2020-03-27 |
2025-02-25 |
艾奥维安制药公司 |
Mtorc1调节剂及其用途
|
|
CN121426814A
(zh)
|
2020-07-21 |
2026-01-30 |
艾奥维安制药公司 |
Mtorc1调节剂及其用途
|